Want to see TSE:CL full AI Analyst Report?
CL Stock Chart & Stats
C$1.26
-C$0.07(-4.76%)
At close: 4:00 PM EST
C$1.26
-C$0.07(-4.76%)
Day’s Range― - ―
52-Week RangeC$0.60 - C$3.12
Previous CloseN/A
Volume48.59K
Average Volume (3M)177.23K
Market Cap
C$535.81M
Enterprise ValueC$808.70M
Total Cash (Recent Filing)C$63.62M
Total Debt (Recent Filing)C$587.20M
Price to Earnings (P/E)―
Beta2.10
Next Earnings
Aug 06, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding354,225,600
10 Day Avg. Volume143,093
30 Day Avg. Volume177,234
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.22
Price to Sales (P/S)0.62
P/FCF Ratio10.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$2.57Price Target Upside103.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.07
Revenue Forecast (FY)C$653.47M
Bulls Say, Bears Say
Bulls Say
EarningsBetter-than-expected gross margins driving EBITDA slightly ahead of forecast.
Financial PerformanceAdjusted EBITDA of $39.8M was above the estimate of $36.0M.
International ExpansionCresco announced that it will be entering international markets with plans to launch its branded flower into Germany.
Bears Say
Margin ExpectationsManagement expects margins to return to Q1 levels for the second half of the year.
Revenue DeclineRevenue of $163.6M was down 1.3% sequentially and down 11.2% year-over-year.
CL FAQ
What was Cresco Labs OTC’s price range in the past 12 months?
Cresco Labs OTC lowest stock price was C$0.60 and its highest was C$3.12 in the past 12 months.
What is Cresco Labs OTC’s market cap?
Cresco Labs OTC’s market cap is C$535.81M.
When is Cresco Labs OTC’s upcoming earnings report date?
Cresco Labs OTC’s upcoming earnings report date is Aug 06, 2026 which is in 32 days.
How were Cresco Labs OTC’s earnings last quarter?
Cresco Labs OTC released its earnings results on May 08, 2026. The company reported -C$0.057 earnings per share for the quarter, missing the consensus estimate of -C$0.028 by -C$0.028.
Is Cresco Labs OTC overvalued?
According to Wall Street analysts Cresco Labs OTC’s price is currently Undervalued.
Does Cresco Labs OTC pay dividends?
Cresco Labs OTC does not currently pay dividends.
What is Cresco Labs OTC’s EPS estimate?
Cresco Labs OTC’s EPS estimate is -0.02.
How many shares outstanding does Cresco Labs OTC have?
Cresco Labs OTC has 354,225,600 shares outstanding.
What happened to Cresco Labs OTC’s price movement after its last earnings report?
Cresco Labs OTC reported an EPS of -C$0.057 in its last earnings report, missing expectations of -C$0.028. Following the earnings report the stock price went down -5.333%.
Which hedge fund is a major shareholder of Cresco Labs OTC?
Currently, no hedge funds are holding shares in TSE:CL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cresco Labs Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$2.57 (103.96% Upside)
C$2.57 (103.96% Upside)
Blogger Sentiment
Bullish
TSE:CL Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth C$86.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 17.6%
Last 30 Days ▲ 19.5%
Last 30 Days ▲ 19.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
60.58%
12-Months-Change
Fundamentals
Return on Equity
-35.26%
Trailing 12-Months
Asset Growth
-12.11%
Trailing 12-Months
Company Description
Cresco Labs OTC
Cresco Labs Inc. engages in cultivating medical grade cannabis, manufacturing medical products derived from cannabis cultivation, and distributing such products to medical or adult use consumers. It focuses on regulatory compliance while working to develop condition-specific strains of cannabis and non-invasive delivery methods. The company was founded by Charles Bachtel, Joseph Caltabiano, Dominic Sergi, Rob Sampson, and Brian McCormack on July 6, 1990 and is headquartered in Chicago, IL.
CL Company Deck
CL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a cautiously optimistic outlook: management delivered solid Q1 margins and EBITDA from a streamlined cost structure, achieved meaningful operational and licensing wins (PA store expansion, Ohio openings, Kentucky harvest, Texas license) and provided constructive Q2 growth guidance (~+10% revenue). Offsets include near-term revenue headwinds from the planned California exit and Michigan excise tax, ongoing pricing compression, seasonal cash flow timing, and unresolved regulatory details around rescheduling (including the scope and timing of 280E relief). On balance, operational momentum, accretive M&A activity, and licensing progress outweigh the short-term market and regulatory challenges.View all TSE:CL earnings summariesCL Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
C$2.57
▲(103.96% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Options Prices
Currently, No data available
---









